Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics Inc (NASDAQ: JSPR) is a clinical-stage biotechnology company pioneering safer conditioning agents for stem cell transplants and gene therapies. This dedicated news hub provides investors and medical professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships central to advancing curative treatments.
Discover comprehensive coverage of JSPR's progress in hematopoietic stem cell research, including trial results for jsp191 and related therapeutic platforms. Our curated collection features press releases on FDA interactions, collaboration announcements with research institutions, and analyses of scientific breakthroughs in antibody-based conditioning.
Key updates include progress reports on:
• Phase clinical trials evaluating novel conditioning regimens
• Strategic licensing agreements enhancing therapeutic pipelines
• Peer-reviewed research publications validating scientific approaches
• Financial disclosures supporting continued R&D efforts
Bookmark this page for direct access to Jasper Therapeutics' official communications and third-party analyses, carefully vetted for accuracy and relevance. Check regularly for developments that could influence the future of stem cell transplantation protocols and gene therapy accessibility.
Jasper Therapeutics (Nasdaq: JSPR) reported positive preliminary Phase 1b ETESIAN results for briquilimab in allergic asthma and closed an internal BEACON investigation. A single 180mg subcutaneous dose produced marked reductions in sputum eosinophils and serum tryptase and improved Early and Late Asthmatic Response (LAR %Max FEV1 +10.4% at 6 weeks, +8.7% at 12 weeks versus baseline). Briquilimab was well tolerated. The BEACON probe found no drug product issues; Jasper concluded the anomalous lack of CSU efficacy in 10 US patients likely reflected patient selection (9 of 10 likely not mast cell-driven). Jasper expects additional BEACON data in Q1 2026 and plans Phase 2b CSU dosing selection mid-2026.
Jasper Therapeutics (NASDAQ:JSPR) will host an investor webinar on Tuesday, December 2, 2025 at 8:00 am ET to present preliminary ETESIAN asthma data and findings from its investigation into anomalous BEACON CSU results reported in July. The session will include remarks from Jasper management and Dr. Martin Metz, M.D., lead EU investigator in BEACON, followed by a live Q&A. Registration is required and presentation slides plus live and archived webcast links will be posted on Jasper's Investor Relations Events page.
Jasper Therapeutics (Nasdaq: JSPR) reported Q3 2025 results and a corporate update on Nov 10, 2025. Key financials: $50.9M cash as of Sept 30, 2025 and a $30M underwritten offering that the company says extends cash runway through H1 2026. Q3 operating items included R&D $14.4M, G&A $4.8M, and a net loss $18.7M (loss per share $1.13).
Clinically, Jasper is investigating anomalous efficacy in two BEACON cohorts (240mg Q8W and 240mg/180mg Q8W) and reports preliminary findings that the anomalies do not appear related to drug substance or drug product. The company plans final investigation conclusions in Q4 2025, initial ETESIAN asthma data in Q4 2025, and additional BEACON/OLE updates in early Q1 2026, aiming to select dose and commence a Phase 2b CSU study mid-2026.
Jasper Therapeutics (Nasdaq: JSPR) announced management will present at four investor conferences in November–December 2025: UBS Global Healthcare (Nov 9–12), Stifel Healthcare (presentation Nov 11, 4:00 PM ET, presentation), TD Cowen Immunology & Inflammation (presentation Nov 12, 3:30 PM ET, fireside chat) and Evercore Healthcare (presentation Dec 3, 3:00 PM ET, fireside chat).
Live webcasts will be available on Jasper's Investor Relations "News & Events – Events" page and archived replays will be posted for 30 days after each live broadcast.
Jasper Therapeutics (NASDAQ:JSPR), a clinical-stage biotech company developing briquilimab for mast cell driven diseases, has announced the pricing of a $30 million public offering. The offering includes 11.67 million shares of common stock and warrants at $2.43 per share, plus 675,000 pre-funded warrants.
The common warrants will have an exercise price of $2.92 per share, exercisable after six months for four years. The proceeds will fund briquilimab's development for conditions including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, along with general corporate expenses. The offering is expected to close around September 22, 2025, with TD Cowen acting as sole book-running manager.
Jasper Therapeutics (Nasdaq: JSPR), a clinical-stage biotech company, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock, pre-funded warrants, and accompanying common warrants. TD Cowen will serve as the sole book-running manager.
The company plans to use the proceeds to advance the development of briquilimab, their novel antibody therapy targeting KIT (CD117). This therapy is being developed for mast cell-driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. Additional funds will support general corporate purposes, including capital expenditures and working capital.
Jasper Therapeutics (NASDAQ:JSPR), a clinical stage biotech company, will participate in two major investor conferences in September 2025. The company, which is developing briquilimab, a novel antibody therapy targeting KIT (CD117) for mast cell driven diseases, will present at the Cantor Fitzgerald Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 9.
Both presentations will be in fireside chat format and will be available via webcast on Jasper's Investor Relations website, with replays accessible for 30 days after the events.
Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2025 financial results and provided updates on briquilimab, its novel antibody therapy targeting c-Kit. The company reported strong efficacy data in chronic urticaria trials, with 89% complete response rate in CSU patients across 240mg and 360mg single-dose cohorts, and 92% complete response in CIndU patients in the 180mg SPOTLIGHT cohort.
However, the company is investigating anomalous results in two BEACON study cohorts where 11 of 13 patients showed no UAS7 reduction, potentially due to product lot variability. Jasper implemented a 50% workforce reduction to focus on urticaria programs and reported Q2 financials with $39.5M cash position and a net loss of $26.7M. The planned Phase 2b CSU study is now delayed to mid-2026.
Jasper Therapeutics (Nasdaq: JSPR) announced a significant corporate reorganization to extend its cash runway. The company is implementing a 50% workforce reduction and will focus exclusively on developing briquilimab for chronic urticaria programs. As part of the restructuring, Dr. Edwin Tucker will step down as Chief Medical Officer, with Dr. Daniel Adelman taking over as Acting CMO effective August 1, 2025.
The company is halting all other clinical and preclinical programs, including the ETESIAN study in asthma, SCID study, and ongoing investigator-sponsored studies. Jasper will concentrate resources on completing the BEACON, SPOTLIGHT and open label extension studies for briquilimab in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), where the treatment has shown promising results with rapid, deep, and durable responses.
Jasper Therapeutics (NASDAQ:JSPR) reported mixed clinical data from its briquilimab studies in Chronic Spontaneous Urticaria (CSU). In the single-dose cohorts (240mg and 360mg), 8 of 9 participants (89%) achieved complete response, with 78% showing clinical response by week 2. The open-label extension study using 180mg Q8W showed 73% complete response rate at 12 weeks.
However, results from the 240mg Q8W and 240mg followed by 180mg Q8W cohorts were confounded by issues with one drug product lot. The company is investigating the affected lot and will enroll 10-12 additional patients across these cohorts. Due to the same lot issue, Jasper is halting the ETESIAN asthma study and SCID development, implementing cost-cutting measures. The Phase 2b CSU study is now delayed until mid-2026.
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
